QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Price Target & Analyst Ratings

$8.14
+0.48 (+6.27%)
(As of 06/7/2023 ET)
Compare
Today's Range
$7.57
▼
$8.17
50-Day Range
$6.41
▼
$9.58
52-Week Range
$3.46
▼
$9.82
Volume
796,999 shs
Average Volume
570,181 shs
Market Capitalization
$411.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.29
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Marinus Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$26.29
222.92% Upside
High Prediction$42.00
Average Prediction$26.29
Low Prediction$18.00
TypeCurrent
6/7/22 to 6/7/23		1 Month Ago
5/8/22 to 5/8/23		3 Months Ago
3/9/22 to 3/9/23		1 Year Ago
6/7/21 to 6/7/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$26.29$24.29$27.50$32.14
Predicted Upside222.92% Upside283.10% Upside312.95% Upside260.35% Upside
Get Marinus Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.


MRNS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRNS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Marinus Pharmaceuticals Stock vs. The Competition

TypeMarinus PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyBuyHold
Predicted Upside240.93% Upside1,240.79% Upside221.58% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/12/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$50.00 ➝ $42.00+409.71%
3/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy$27.00+283.52%
3/8/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Outperform$19.00 ➝ $18.00+155.68%
3/8/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$23.00 ➝ $22.00+212.50%
3/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight$28.00+297.73%
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$27.00 ➝ $23.00+307.08%
11/9/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$32.00 ➝ $24.00+416.13%
(Data available from 6/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MRNS Price Target - Frequently Asked Questions

What is Marinus Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Marinus Pharmaceuticals stock is Buy based on the current 6 buy ratings for MRNS. The average twelve-month price prediction for Marinus Pharmaceuticals is $26.29 with a high price target of $42.00 and a low price target of $18.00. Learn more on MRNS's analyst rating history.

Do Wall Street analysts like Marinus Pharmaceuticals more than its competitors?

Analysts like Marinus Pharmaceuticals more than other Medical companies. The consensus rating score for Marinus Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how MRNS compares to other companies.

Does Marinus Pharmaceuticals's stock price have much upside?

According to analysts, Marinus Pharmaceuticals's stock has a predicted upside of 301.26% based on their 12-month price targets.

What analysts cover Marinus Pharmaceuticals?

Marinus Pharmaceuticals has been rated by Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MRNS) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -